![](/images/graphics-bg.png)
The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression : An Open-Label Trial
Joint Authors
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-08-01
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Natural & Life Sciences (Multidisciplinary)
Medicine
Information Technology and Computer Science
Abstract EN
Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression.
Although the efficacy of adjunctive pramipexole treatment has been demonstrated in treatment-resistant bipolar depression, such data are scarce for major depressive disorder (MDD).
We recruited 17 patients with DSM-IV major depressive episode who have failed to respond to previous treatment with a selective serotonin reuptake inhibitor.
Five patients were diagnosed as having bipolar II disorder and 12 as having unipolar MDD.
Patients were monitored at an ambulatory care facility every two weeks until 12 weeks.
Pramipexole was added to existing medication.
Depression severity was assessed with the Hamilton Depression Rating Scale 21-item version (HDRS-21).
The mean maximum dosage of pramipexole was 1.6 mg (SD 0.9).
The HDRS-21 total score decreased from 19.4 (SD 3.8) at baseline to 7.2 (SD 5.4) at endpoint (P<0.000001).
Twelve patients (71%) were responders based on the definition of 50% or more reduction in the HDRS-21 score.
Ten patients (59%) remitted (HDRS-21 total score at endpoint <8).
These results were almost unchanged when the sample was confined to patients with MDD.
No serious adverse events were observed.
Our findings indicate that pramipexole augmentation therapy may be effective and well tolerated in refractory depressed patients.
American Psychological Association (APA)
Hori, Hiroaki& Kunugi, Hiroshi. 2012. The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression : An Open-Label Trial. The Scientific World Journal،Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-466852
Modern Language Association (MLA)
Hori, Hiroaki& Kunugi, Hiroshi. The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression : An Open-Label Trial. The Scientific World Journal No. 2012 (2012), pp.1-8.
https://search.emarefa.net/detail/BIM-466852
American Medical Association (AMA)
Hori, Hiroaki& Kunugi, Hiroshi. The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression : An Open-Label Trial. The Scientific World Journal. 2012. Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-466852
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-466852